Overview

Efficacy and Safety of Chidamide in CBF Leukemia

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

In this open-label, randomized, prospective clinical trial, CBF acute myeloid leukemia (AML) patients who have reached CR are randomised into two groups and receive high-dose cytarabine (HDAC) or high-dose cytarabine plus chidamide.The safety and efficacy of chidamide is evaluated.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Treatments:

Cytarabine